Klotho: A Literature Course in Six Modules

This course organises the published klotho literature into six modules. It does not describe a protocol, a product, or an outcome any individual should expect; it summarises what investigators set out to measure and what they reported. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health condition or treatment decision. Each module closes with an explicit statement of what the evidence in that module cannot support.

Module 1: What Klotho Is and How It Has Been Studied

The word "klotho" appears online most often alongside the word "peptide," but the biochemical literature describes klotho as a large single-pass transmembrane glycoprotein rather than a short synthetic peptide chain. A 2022 review of klotho pathobiology described the membrane-anchored form, the shed soluble form generated when the extracellular domain is cleaved, and the therapeutic concepts that have been proposed around both, noting that soluble klotho circulates and can act at a distance from the tissue that produced it (PMID 35903083).

Origin of the research programme

Much of the field traces back to mouse genetics. A 2005 report in Science described mice engineered to overexpress klotho and reported extended lifespan together with evidence that the klotho protein acted as a circulating hormone that suppressed insulin and insulin-like growth factor 1 signalling (PMID 16123266). That same report framed increased resistance to oxidative stress as a candidate contributor to the phenotype the researchers observed (PMID 16123266).

Forms and family members

Reviews distinguish α-klotho, discussed mainly in kidney, mineral and cardiovascular contexts, from related family members; a 2024 review in Nature Reviews Cardiology examined α-klotho specifically as the co-receptor that confers tissue specificity on fibroblast growth factor 23 (FGF23) signalling at the intersection of kidney and cardiovascular disease (PMID 37443358).

Where it is expressed

Because most early work was rodent-based, a 2015 study in The Journal of Clinical Endocrinology and Metabolism surveyed human tissue samples specifically to map where α-klotho is expressed rather than extrapolating from mice (PMID 26280509). Expression is also regulated rather than fixed: a 2025 study in Biomolecules used renal cell lines to examine how mineralocorticoid receptor signalling regulates klotho production (PMID 41301427).

Limits of the evidence in Module 1

Definitional work establishes what klotho is and where the protein appears; it does not establish that administering klotho, in any form, changes human health outcomes. Tissue-expression mapping describes anatomy, not causation, and lifespan genetics in engineered mice is a model system, not a human finding.

Module 2: Mechanism as Described in the Literature

Mechanistic accounts of klotho cluster into several distinct threads, each supported by a different body of work.

Mineral metabolism and FGF23

The most developed thread is endocrine. The 2024 Nature Reviews Cardiology review described α-klotho as the obligate co-receptor for FGF23 and traced how disturbances in the FGF23–klotho axis accompany chronic kidney disease and relate to cardiovascular pathology (PMID 37443358). A 2021 review in Biochemistry (Moscow) likewise organised the evidence linking klotho protein to the cardiovascular system, including vascular and mineral-handling pathways (PMID 33832412).

Inflammation

A 2024 review in Cells collected the evidence for an anti-inflammatory role of the klotho protein and discussed its relevance to aging biology, summarising work in which klotho intersects with inflammatory signalling pathways (PMID 39272986).

Growth-factor signalling and oxidative stress

The 2005 mouse work reported suppression of insulin and IGF-1 signalling by klotho and proposed oxidative-stress resistance as a downstream consequence (PMID 16123266). The 2022 pathobiology review revisited these mechanisms and connected them to proposals for therapeutic manipulation of klotho (PMID 35903083).

Cell division and tumour biology

A 2020 paper in Genes described an emerging role for klotho in cytokinesis, the final step of cell division (PMID 32899868). A 2023 Chinese-language review summarised research progress on klotho in lung neoplasms, where the protein has been studied in relation to tumour cell behaviour (PMID 37488085).

Bone

A 2017 study in Kidney International examined klotho expression in osteocytes and reported that it participates in the regulation of bone metabolism and bone formation (PMID 28396120).

Limits of the evidence in Module 2

These mechanisms were mapped largely in cells, genetically modified mice and narrative reviews. Mechanistic plausibility does not predict clinical effect, and pathways described in one tissue may not operate the same way in another. Several threads — cell division and tumour biology in particular — cut in more than one direction.

Module 3: Reported Outcomes, Study by Study

The table below lists what each verified primary study or review examined, the model used, and what the authors reported. No entry should be read as a promise of benefit.

Limits of the evidence in Module 3

Every row above is either a preclinical experiment or a review of preclinical and observational work. None of the verified papers reported a randomised controlled trial of administered klotho in humans, and none reported a human dose. Where reviews describe associations between low circulating klotho and disease states, association is not the same as demonstrating that raising klotho changes an outcome.

Module 4: Klotho Side Effects: What Studies Report

There is no human adverse-event dataset for administered klotho in the verified literature, because the verified literature contains no human administration trial. What can be described are safety-relevant signals raised inside the biology itself.

• Cell-cycle involvement. Because a 2020 review described klotho as participating in cytokinesis, the final stage of cell division, researchers have framed klotho as a protein that intersects with proliferation control (PMID 32899868).
• Tumour biology. A 2023 review summarised klotho research in lung neoplasms, an area where the protein has been examined in relation to tumour cell behaviour rather than as an established therapy (PMID 37488085).
• Mineral and endocrine coupling. The 2024 Nature Reviews Cardiology review described the FGF23–klotho axis as tightly coupled to phosphate and mineral handling in kidney and cardiovascular disease, meaning manipulation of one element of that axis has system-wide implications (PMID 37443358).
• Skeletal effects. The 2017 osteocyte study reported that klotho expression in bone-resident cells influenced bone metabolism and bone formation, indicating that klotho signalling is not confined to a single organ (PMID 28396120).
• Reproductive cell biology. The 2023 porcine oocyte study examined klotho protein addition and klotho knockdown at different maturation stages, demonstrating that the protein's effects in that system depended on developmental timing (PMID 37905414).

Limits of the evidence in Module 4

Absence of reported adverse events is not evidence of safety; it reflects the absence of trials designed to detect them. No verified paper reported injection-site reactions, immunogenicity, laboratory abnormalities or dose-limiting toxicity in humans, because no verified paper administered klotho to humans.

Module 5: Pharmacokinetics, Where Data Exist

Pharmacokinetic description requires an administered dose, a route and serial sampling. The verified literature supplies none of these for human use. What it supplies instead is endogenous kinetics at the level of protein handling: the 2022 pathobiology review described how the extracellular domain of membrane klotho is shed to generate a soluble circulating form, and discussed that soluble form as the basis for proposed therapeutic strategies (PMID 35903083).

Tissue-level data provide the other half of the picture. The 2015 human tissue study characterised where α-klotho is expressed in people, which bears on which compartments could plausibly generate or respond to the protein (PMID 26280509). Production is dynamic rather than constitutive: the 2025 renal cell line study examined mineralocorticoid receptor signalling as a regulator of klotho production (PMID 41301427).

Limits of the evidence in Module 5

No verified paper reported half-life, bioavailability, clearance, volume of distribution, Cmax or Tmax for klotho given as a therapeutic protein in humans or animals. Any figure circulating outside the peer-reviewed record for these parameters is not traceable to the papers cited here. Klotho is also a large glycoprotein, and reviews treat delivery as an unresolved question rather than a solved one (PMID 35903083).

Module 6: Regulatory Status, Stated Factually

Several factual points can be separated from the science:

1. No approved klotho drug. There is no klotho protein or klotho-derived product approved by the US Food and Drug Administration, the European Medicines Agency or comparable regulators for any indication.
2. Research-use-only material. Recombinant klotho protein is supplied by laboratory reagent companies under research-use-only (RUO) labelling. RUO material is not manufactured, tested or released as a human medicine and carries no regulatory finding of safety or efficacy.
3. Compounding. Compounded preparations in the United States are made from bulk drug substances that appear on FDA's applicable lists or that are components of approved products. Klotho is not an approved active ingredient, and the reviews cited here describe klotho manipulation as a therapeutic concept under investigation rather than an available treatment (PMID 35903083).
4. Biomarker context. Klotho and FGF23 appear in the clinical literature largely as measured biomarkers in kidney and cardiovascular disease, as reviewed in 2024 (PMID 37443358), and separately in reviews of the aging heart (PMID 40799848).

This section describes publicly stated regulatory categories and is not legal advice; rules differ by country and change over time.

Limits of the evidence in Module 6

Regulatory status describes paperwork, not biology. A compound being unapproved does not mean it is dangerous, and a compound being sold as a research reagent does not mean it has been evaluated for human use. Neither status substitutes for trial data.

What the Studies Did Not Test

Reading the verified record as a whole, the gaps are as important as the findings:

• No verified study administered klotho to human participants, so no human dose, schedule or route has been reported.
• No verified study measured human endpoints such as cognition, body composition, exercise capacity or subjective aging after klotho administration.
• The 2005 lifespan finding was reported in genetically engineered mice that overexpressed klotho from conception, not in animals or people given a protein later in life (PMID 16123266).
• Review articles on inflammation (PMID 39272986) and on the cardiovascular system (PMID 33832412) synthesised existing work rather than generating new clinical outcome data.
• No verified study reported long-term safety follow-up, drug interactions, immunogenicity testing, or use in pregnancy.

What the literature supports today is a detailed mechanistic map of an endogenous protein with roles in mineral metabolism, inflammation, cell division and bone, studied mainly in mice, cells and human tissue surveys. Claims that go beyond that map are not supported by the papers cited on this page.

References

• Suppression of aging in mice by the hormone Klotho (Science, 2005)
• α-Klotho Expression in Human Tissues (The Journal of Clinical Endocrinology and Metabolism, 2015)
• Klotho expression in osteocytes regulates bone metabolism and controls bone formation (Kidney International, 2017)
• Klotho Exerts an Emerging Role in Cytokinesis (Genes, 2020)
• Klotho Protein and Cardio-Vascular System (Biochemistry. Biokhimiia, 2021)
• Pathobiology of the Klotho Antiaging Protein and Therapeutic Considerations (Frontiers in Aging, 2022)
• FGF23 and klotho at the intersection of kidney and cardiovascular disease (Nature Reviews Cardiology, 2024)
• Research Progress of Klotho in Lung Neoplasms (Chinese Journal of Lung Cancer, 2023)
• Effects of klotho protein or klotho knockdown in porcine oocytes at different stages (Zygote, 2023)
• Anti-Inflammatory Role of the Klotho Protein and Relevance to Aging (Cells, 2024)
• The aging heart: exploring the role of Klotho in cardiac health/function (The Journal of Cardiovascular Aging, 2024)
• Regulation of Klotho Production by Mineralocorticoid Receptor Signaling in Renal Cell Lines (Biomolecules, 2025)